1. Home
  2. PDC vs IMNN Comparison

PDC vs IMNN Comparison

Compare PDC & IMNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

PDC

Perpetuals.com Ltd American Depositary Shares

N/A

Current Price

$7.00

Market Cap

13.9M

Sector

Technology

ML Signal

N/A

Logo Imunon Inc.

IMNN

Imunon Inc.

HOLD

Current Price

$2.81

Market Cap

11.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PDC
IMNN
Founded
2018
1982
Country
Japan
United States
Employees
20
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
13.9M
11.5M
IPO Year
N/A
2000

Fundamental Metrics

Financial Performance
Metric
PDC
IMNN
Price
$7.00
$2.81
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$10.00
AVG Volume (30 Days)
111.6K
37.7K
Earning Date
07-01-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.46
$0.37
52 Week High
$7.90
$9.32

Technical Indicators

Market Signals
Indicator
PDC
IMNN
Relative Strength Index (RSI) 61.44 37.33
Support Level $3.99 $2.52
Resistance Level N/A $3.24
Average True Range (ATR) 0.86 0.17
MACD 0.22 -0.02
Stochastic Oscillator 81.15 16.00

Price Performance

Historical Comparison
PDC
IMNN

About PDC Perpetuals.com Ltd American Depositary Shares

Earlyworks Co Ltd is a blockchain-based technology company. It builds products, delivers services, and develops solutions based on a proprietary grid ledger system to leverage blockchain technology in various business settings, including advertisement tracking, online visitor management, and sales of non-fungible tokens. The company's customers represent a diverse range of industries, such as information technology, shipping, real estate, entertainment, cosmetics, and chemical products.

About IMNN Imunon Inc.

Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective and durable responses across a broad array of human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas, is developed for the coding of proteins and cytokines in the treatment of solid tumors. The second modality, PlaCCine, is developed for the coding of viral antigens that can elicit an immunological response. The company's clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer.

Share on Social Networks: